These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status. Thompson EM; Landi D; Ashley D; Keir ST; Bigner D J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661 [TBL] [Abstract][Full Text] [Related]
18. Exploring prognostic factors and treatment strategies for long-term survival in pleomorphic xanthoastrocytoma patients. Lee C; Byeon Y; Kim GJ; Jeon J; Hong CK; Kim JH; Kim YH; Cho YH; Hong SH; Chong SJ; Song SW Sci Rep; 2024 Feb; 14(1):4615. PubMed ID: 38409363 [TBL] [Abstract][Full Text] [Related]
19. Rare clinical presentations of pleomorphic xanthoastrocytoma with a high proliferative index: Two case reports. Nagaishi M; Nakae R; Fujii Y; Inoue Y; Sugiura Y; Takano I; Tanaka Y; Suzuki K Medicine (Baltimore); 2020 Jan; 99(3):e18880. PubMed ID: 32011515 [TBL] [Abstract][Full Text] [Related]
20. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]